Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer

Jinsong Liu, Constance T. Albarracin, Ki Hong Chang, Jennifer A. Thompson-Lanza, Wenxin - Zheng, David M. Gershenson, Russell Broaddus, Rajyalakshmi Luthra

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Microsatellite instability and loss of heterozygosity has been implicated in ovarian carcinogenesis. The reported frequency of microsatellite instability in human ovarian cancer varies significantly owing to the use of heterogeneous tumor histotypes and various microsatellite markers in different laboratories. In this study, we determined the frequency of microsatellite instability in 74 ovarian endometrioid carcinomas using four microsatellite markers (BAT25, BAT26, D5S346, D17S250), and examined hMLH1 and hMSH2 protein expression. In all, 20% of the tumors were microsatellite instability high (two or more markers showing instability) and 12% were microsatellite instability low (one marker showed instability). Loss of hMLH1 and/or hMSH2 expression was found in nine of 15 microsatellite instability-high tumors. The microsatellite instability-high phenotype tended to occur more frequently in low-grade tumors (P=0.053), but did not correlate with clinical stage. Totally, 38% of cases also displayed loss of heterozygosity at D17S250; this loss of heterozygosity was associated with high clinical stage (P=0.097). Our results indicate that both microsatellite and loss of heterozygosity at D17S250 are involved in the development of ovarian endometrioid carcinoma.

Original languageEnglish (US)
Pages (from-to)75-80
Number of pages6
JournalModern Pathology
Volume17
Issue number1
DOIs
StatePublished - Jan 2004
Externally publishedYes

Fingerprint

Microsatellite Instability
Ovarian Neoplasms
Loss of Heterozygosity
Proteins
Microsatellite Repeats
Endometrioid Carcinoma
Neoplasms
Carcinogenesis
Phenotype

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Liu, J., Albarracin, C. T., Chang, K. H., Thompson-Lanza, J. A., Zheng, W. ., Gershenson, D. M., ... Luthra, R. (2004). Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Modern Pathology, 17(1), 75-80. https://doi.org/10.1038/modpathol.3800017

Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. / Liu, Jinsong; Albarracin, Constance T.; Chang, Ki Hong; Thompson-Lanza, Jennifer A.; Zheng, Wenxin -; Gershenson, David M.; Broaddus, Russell; Luthra, Rajyalakshmi.

In: Modern Pathology, Vol. 17, No. 1, 01.2004, p. 75-80.

Research output: Contribution to journalArticle

Liu, J, Albarracin, CT, Chang, KH, Thompson-Lanza, JA, Zheng, W, Gershenson, DM, Broaddus, R & Luthra, R 2004, 'Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer', Modern Pathology, vol. 17, no. 1, pp. 75-80. https://doi.org/10.1038/modpathol.3800017
Liu, Jinsong ; Albarracin, Constance T. ; Chang, Ki Hong ; Thompson-Lanza, Jennifer A. ; Zheng, Wenxin - ; Gershenson, David M. ; Broaddus, Russell ; Luthra, Rajyalakshmi. / Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. In: Modern Pathology. 2004 ; Vol. 17, No. 1. pp. 75-80.
@article{c8e25c8a52744b5dbed93037a9871d76,
title = "Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer",
abstract = "Microsatellite instability and loss of heterozygosity has been implicated in ovarian carcinogenesis. The reported frequency of microsatellite instability in human ovarian cancer varies significantly owing to the use of heterogeneous tumor histotypes and various microsatellite markers in different laboratories. In this study, we determined the frequency of microsatellite instability in 74 ovarian endometrioid carcinomas using four microsatellite markers (BAT25, BAT26, D5S346, D17S250), and examined hMLH1 and hMSH2 protein expression. In all, 20{\%} of the tumors were microsatellite instability high (two or more markers showing instability) and 12{\%} were microsatellite instability low (one marker showed instability). Loss of hMLH1 and/or hMSH2 expression was found in nine of 15 microsatellite instability-high tumors. The microsatellite instability-high phenotype tended to occur more frequently in low-grade tumors (P=0.053), but did not correlate with clinical stage. Totally, 38{\%} of cases also displayed loss of heterozygosity at D17S250; this loss of heterozygosity was associated with high clinical stage (P=0.097). Our results indicate that both microsatellite and loss of heterozygosity at D17S250 are involved in the development of ovarian endometrioid carcinoma.",
author = "Jinsong Liu and Albarracin, {Constance T.} and Chang, {Ki Hong} and Thompson-Lanza, {Jennifer A.} and Zheng, {Wenxin -} and Gershenson, {David M.} and Russell Broaddus and Rajyalakshmi Luthra",
year = "2004",
month = "1",
doi = "10.1038/modpathol.3800017",
language = "English (US)",
volume = "17",
pages = "75--80",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer

AU - Liu, Jinsong

AU - Albarracin, Constance T.

AU - Chang, Ki Hong

AU - Thompson-Lanza, Jennifer A.

AU - Zheng, Wenxin -

AU - Gershenson, David M.

AU - Broaddus, Russell

AU - Luthra, Rajyalakshmi

PY - 2004/1

Y1 - 2004/1

N2 - Microsatellite instability and loss of heterozygosity has been implicated in ovarian carcinogenesis. The reported frequency of microsatellite instability in human ovarian cancer varies significantly owing to the use of heterogeneous tumor histotypes and various microsatellite markers in different laboratories. In this study, we determined the frequency of microsatellite instability in 74 ovarian endometrioid carcinomas using four microsatellite markers (BAT25, BAT26, D5S346, D17S250), and examined hMLH1 and hMSH2 protein expression. In all, 20% of the tumors were microsatellite instability high (two or more markers showing instability) and 12% were microsatellite instability low (one marker showed instability). Loss of hMLH1 and/or hMSH2 expression was found in nine of 15 microsatellite instability-high tumors. The microsatellite instability-high phenotype tended to occur more frequently in low-grade tumors (P=0.053), but did not correlate with clinical stage. Totally, 38% of cases also displayed loss of heterozygosity at D17S250; this loss of heterozygosity was associated with high clinical stage (P=0.097). Our results indicate that both microsatellite and loss of heterozygosity at D17S250 are involved in the development of ovarian endometrioid carcinoma.

AB - Microsatellite instability and loss of heterozygosity has been implicated in ovarian carcinogenesis. The reported frequency of microsatellite instability in human ovarian cancer varies significantly owing to the use of heterogeneous tumor histotypes and various microsatellite markers in different laboratories. In this study, we determined the frequency of microsatellite instability in 74 ovarian endometrioid carcinomas using four microsatellite markers (BAT25, BAT26, D5S346, D17S250), and examined hMLH1 and hMSH2 protein expression. In all, 20% of the tumors were microsatellite instability high (two or more markers showing instability) and 12% were microsatellite instability low (one marker showed instability). Loss of hMLH1 and/or hMSH2 expression was found in nine of 15 microsatellite instability-high tumors. The microsatellite instability-high phenotype tended to occur more frequently in low-grade tumors (P=0.053), but did not correlate with clinical stage. Totally, 38% of cases also displayed loss of heterozygosity at D17S250; this loss of heterozygosity was associated with high clinical stage (P=0.097). Our results indicate that both microsatellite and loss of heterozygosity at D17S250 are involved in the development of ovarian endometrioid carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=2442712044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442712044&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3800017

DO - 10.1038/modpathol.3800017

M3 - Article

C2 - 14631366

AN - SCOPUS:2442712044

VL - 17

SP - 75

EP - 80

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 1

ER -